- Thinly-traded small cap Flamel Technologies (FLML +12%) heads north in response to its announcement that it achieved its objective of a single before-bedtime dose of sodium oxybate using its proprietary Micropump technology. A single dose option for sufferers of narcolepsy would eliminate a second dose 2.5 to 4 hours later that is necessary with the current standard of care, Jazz Pharmaceuticals' (JAZZ -0.9%) Xyrem (sodium oxybate). This would be more convenient and would eliminate the disruption in sleep.
- Flamel plans to meet with the FDA before mid-2015 to clarify a regulatory path.
Flamel progresses on single dose narcolepsy treatment
Recommended For You
More Trending News
About AVDL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AVDL | - | - |
Avadel Pharmaceuticals plc |